FRIDAY, JUNE 15, 2018

Sinovac receives commercial approval for flu vaccine in Mexico

Sinovac Biotech, Ltd., a China-based biopharmaceutical company, announced on Thursday that it received a certificate of approval to commercialize its seasonal flu vaccine, Anflu, in Mexico.

The Federal Commission for the Protection Against Sanitary Risk of the Mexico Ministry of Health issued the certificate, which is valid from April 1 through April 1, 2013. Sinovac originally filed the application to distribute Anflu in Mexico in 2005. The company received a good manufacturing practice certificate for its hepatitis A and seasonal flu vaccines on August 11, 2011.

As part of a 2005 distribution agreement, Laboratorios Imperiales S.A. de C.V., a Mexico-based biopharmaceutical company, is the exclusive distributor of Sinovac's vaccine products in Mexico.

"This is a great milestone for Sinovac as we look to continue expanding our commercial efforts worldwide," Weidong Yin, the chairman, president and CEO of Sinovac, said. "We are pleased to receive approval to supply Anflu in the Mexican market, which we perceive as a significant opportunity outside of China. We expect to begin sales planning for Mexican market in conjunction with our partner, Laboratorios Imperiales, in the coming days."

Sinovac focuses on research, manufacturing, development and commercialization of vaccines to protect against human infectious diseases such as mumps, H5N1 pandemic influenza, seasonal influenza, hepatitis A and hepatitis B.